DE69730217T2 - Dha-pharmazeutisches produkt konjugate - Google Patents

Dha-pharmazeutisches produkt konjugate Download PDF

Info

Publication number
DE69730217T2
DE69730217T2 DE69730217T DE69730217T DE69730217T2 DE 69730217 T2 DE69730217 T2 DE 69730217T2 DE 69730217 T DE69730217 T DE 69730217T DE 69730217 T DE69730217 T DE 69730217T DE 69730217 T2 DE69730217 T2 DE 69730217T2
Authority
DE
Germany
Prior art keywords
taxol
conjugate
conjugates
dha
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730217T
Other languages
German (de)
English (en)
Other versions
DE69730217D1 (de
Inventor
O. Matthews BRADLEY
E. Victor SHASHOUA
L. Nigel WEBB
S. Charles SWINDELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Regent Inc
Original Assignee
Luitpold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luitpold Pharmaceuticals Inc filed Critical Luitpold Pharmaceuticals Inc
Publication of DE69730217D1 publication Critical patent/DE69730217D1/de
Application granted granted Critical
Publication of DE69730217T2 publication Critical patent/DE69730217T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69730217T 1996-05-22 1997-05-22 Dha-pharmazeutisches produkt konjugate Expired - Lifetime DE69730217T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US651312 1996-05-22
US08/651,312 US5795909A (en) 1996-05-22 1996-05-22 DHA-pharmaceutical agent conjugates of taxanes
PCT/US1997/008867 WO1997044063A2 (en) 1996-05-22 1997-05-22 Dha-pharmaceutical agent conjugates

Publications (2)

Publication Number Publication Date
DE69730217D1 DE69730217D1 (de) 2004-09-16
DE69730217T2 true DE69730217T2 (de) 2005-07-28

Family

ID=24612392

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730217T Expired - Lifetime DE69730217T2 (de) 1996-05-22 1997-05-22 Dha-pharmazeutisches produkt konjugate

Country Status (10)

Country Link
US (3) US5795909A (OSRAM)
EP (2) EP0909183B1 (OSRAM)
JP (1) JP4402173B2 (OSRAM)
AT (1) ATE273025T1 (OSRAM)
AU (1) AU725759B2 (OSRAM)
CA (1) CA2255614C (OSRAM)
DE (1) DE69730217T2 (OSRAM)
DK (1) DK0909183T3 (OSRAM)
ES (1) ES2222514T3 (OSRAM)
WO (1) WO1997044063A2 (OSRAM)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US20030073642A1 (en) * 1993-02-22 2003-04-17 American Bioscience, Inc. Methods and formulations for delivery of pharmacologically active agents
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
ES2210761T3 (es) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
DE69834937D1 (de) 1997-09-17 2006-07-27 Eisai Co Ltd Antibiotika zur behandlung von magengeschwuren
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
KR20000076105A (ko) * 1998-01-13 2000-12-26 도리이 신이찌로 항생제를 함유한 국소 투여용 항균 조성물
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
FI980901A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
CN1195500C (zh) 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
EP1098634A4 (en) * 1998-07-20 2006-10-25 Smithkline Beecham Corp EPROSARTAN CONTAINING MORE EFFECTIVE FORMULATIONS IN ORAL SOLID PHARMACEUTICAL FORM
ATE481090T1 (de) * 1998-07-28 2010-10-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
CN100444843C (zh) * 1998-08-10 2008-12-24 旭化成制药株式会社 法舒地尔盐酸盐缓释口服制剂
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
JP2002525311A (ja) * 1998-10-01 2002-08-13 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
DE60039410D1 (de) * 1999-01-29 2008-08-21 Takeda Pharmaceutical Verdichtungshammer mit beschichtungsbehandlung
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
EP1163011A2 (en) * 1999-03-09 2001-12-19 Protarga Inc. Fatty acid-anticancer conjugates and uses thereof
US6475984B2 (en) 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
EP2030620A1 (en) * 1999-05-07 2009-03-04 Wockhardt Limited (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
US6197337B1 (en) * 1999-05-10 2001-03-06 Kenneth Weisman Therapeutic uses of abarelix
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
AU5928599A (en) * 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
MXPA02004862A (es) * 1999-11-15 2003-01-28 Pharma Mar Sa Tratamiento de aplidina para canceres.
AU2058701A (en) * 1999-12-02 2001-06-12 F. Hoffmann-La Roche Ag Esters of vitamin D3 and uses thereof
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
AR035026A1 (es) 2000-01-19 2004-04-14 Baker Norton Pharma Uso de pentosan polisulfato en el tratamiento de ciertas condiciones de la prostata
RO121270B1 (ro) * 2000-02-02 2007-02-28 Florida State University Research Foundation, Inc. Taxani substituiţi cu esteri în poziţia c10, ca agenţi antitumorali
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6660750B2 (en) 2000-02-15 2003-12-09 University Of Iowa Research Foundation Flavopiridol methods and compositions for HIV therapy
US6452024B1 (en) 2000-02-22 2002-09-17 Chaichem Pharmaceuticals International Process for extraction and purification of paclitaxel from natural sources
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
AU2002222931A1 (en) 2000-07-19 2002-01-30 University Of Pittsburgh Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin a
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6884777B1 (en) 2000-11-14 2005-04-26 The Nemours Foundation Method for treating respiratory distress syndrome
EP1423107B1 (en) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
US8552054B2 (en) * 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
JP2004528369A (ja) * 2001-05-03 2004-09-16 アラーガン、インコーポレイテッド 向上した薬物動態特性を有する組成物
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
CA2354471A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
SG129990A1 (en) * 2001-08-01 2007-03-20 Univ Florida State Res Found C10 ester substituted taxanes
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
CN100558365C (zh) * 2001-09-27 2009-11-11 特拉维夫大学拉莫特有限公司 共轭的精神抑制药及其用途
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US6730667B2 (en) * 2001-11-26 2004-05-04 William R. Deagle Iontophoresis disc pain blocker
CN1596111A (zh) * 2001-11-29 2005-03-16 桑得医药品公司 减轻化疗引起的不良效果的组合物及方法
PT1471902E (pt) * 2002-01-04 2014-09-09 Sound Pharmaceuticals Inc Métodos para o tratamento da perda de audição
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
JP2005525368A (ja) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
AU2003235931A1 (en) * 2002-05-13 2003-11-11 Takata Seiyaku Co., Ltd. Vintoperol-containing medicinal composition for transdermal administration
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040002663A1 (en) * 2002-06-26 2004-01-01 Reeves William H. Method and system for use in detecting a cancerous and precancerous pathology
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004033478A2 (en) * 2002-10-08 2004-04-22 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004052308A2 (en) * 2002-12-10 2004-06-24 Biosynexus Incorporated Topical anti-infective formulations
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US6759539B1 (en) 2003-02-27 2004-07-06 Chaichem Pharmaceuticals International Process for isolation and purification of paclitaxel from natural sources
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
WO2004093807A2 (en) * 2003-04-22 2004-11-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin vectors
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20040242655A1 (en) * 2003-05-28 2004-12-02 Anziano Paul Q. Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
CA2532807A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
GB2423927A (en) * 2003-08-29 2006-09-13 Cotherix Inc Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
US7223770B2 (en) * 2003-10-29 2007-05-29 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CA2544128A1 (en) * 2003-10-30 2005-05-12 The Research Foundation Of State University Of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
GB0326180D0 (en) * 2003-11-11 2003-12-17 Leuven K U Res & Dev Biocompatible coating of medical devices
SV2006002010A (es) 2004-02-13 2006-08-23 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
JP2007527432A (ja) 2004-03-05 2007-09-27 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド Ｃ７ラクチルオキシ置換タキサン
US20100173864A1 (en) * 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
GB0413729D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
ES2519690T3 (es) * 2004-09-24 2014-11-07 University Of Maryland, Baltimore Método de tratamiento de envenenamiento por organosfósforo
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
AU2006212738B2 (en) 2005-02-09 2012-04-05 Mitotek, Llc Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
AU2006220626A1 (en) * 2005-03-08 2006-09-14 Sound Pharmaceuticals Incorporated Methods and compositions for treating cancer
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
JP2008540394A (ja) 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
US20090298814A1 (en) * 2005-06-07 2009-12-03 Ramot At Tel Aviv Univeristy Ltd Novel salts of conjugated psychotropic drugs and processes of preparing same
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
EP1951248A4 (en) * 2005-11-14 2011-05-25 Peter D Winch NEW COLORED SOLUTIONS OF INJECTABLE MEDICINAL PRODUCTS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS
CA2632149C (en) * 2005-12-01 2011-11-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
SG174050A1 (en) * 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US20070248548A1 (en) * 2006-04-19 2007-10-25 Blondino Frank E Stable hydroalcoholic oral spray formulations and methods
PL2020996T3 (pl) * 2006-05-16 2012-04-30 Gilead Sciences Inc Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
CA2659521A1 (en) 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
WO2008014456A2 (en) * 2006-07-28 2008-01-31 Collegium Pharmaceutical, Inc. Combination therapy for otitis with antiseptic and ph adjustment
WO2008021242A2 (en) * 2006-08-10 2008-02-21 The Research Foundation Of State University Of New York Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CA2667211A1 (en) 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
SI2125786T1 (sl) * 2006-12-21 2011-05-31 Pfizer Prod Inc Sukcinat sol 2-((4-(1-metil-4-(piridin-4-il)-1H-pirazol-3-il)fenoksi)metil)kinolina
EP2124897A4 (en) * 2006-12-22 2012-05-09 Novadel Pharma Inc SPRAYING, ORAL, STABLE, SPRAY PREPARATIONS AND ASSOCIATED METHODS
JP2010514841A (ja) * 2007-01-03 2010-05-06 グレン ブイ． コルネット， 肺疾患および心疾患の処置におけるシクレタニンおよびｐｋｃ阻害剤
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
EP2167493A1 (en) * 2007-03-09 2010-03-31 Novartis AG Salts of 3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-i-yl) -quinazolin-4-yl]-pyrrole-2,5-di one
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
WO2008141264A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
RS53245B2 (sr) * 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
US8067632B2 (en) * 2007-07-26 2011-11-29 The Board Of Trustees Of The Leland Stanford Junior University Process to produce prostratin and structural or functional analogs thereof
US8399420B2 (en) * 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
CA2709219A1 (en) * 2007-12-12 2009-06-18 Ultimorphix Technologies B.V. Solid forms of tenofovir disoproxil
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
EP2252578B1 (en) 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
US8242166B2 (en) 2008-03-31 2012-08-14 Florida State University Research Foundation, Inc. C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
AU2009247782C1 (en) * 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
CA2729186C (en) 2008-07-08 2018-01-16 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
HRP20120700T1 (hr) 2008-07-08 2012-09-30 Gilead Sciences SOLI SPOJEVA INHIBITORA HIV-a
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
DK3279195T3 (en) * 2008-12-01 2020-08-17 Oyster Point Pharma Inc Synthesis and novel salt forms of (R)-5-((E)-2-(pyrrolidin-3-ylvinyl)pyrimidine
CN102395275A (zh) * 2008-12-11 2012-03-28 拜欧维斯塔公司 用四环吡嗪并吲哚治疗多发性硬化症的方法
PL2379497T3 (pl) * 2008-12-18 2014-01-31 Novartis Ag Sól hemifumaranowa kwasu 1-[4[1-(4-cykloheksylo-3trifluorometylobenzyloksyimino)etylo]2-etylobenzylo]-azetydyno-3-karboksylowego
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
CN102458112A (zh) * 2009-04-10 2012-05-16 阿布拉科斯生物科学有限公司 纳米颗粒制剂及其用途
AR076590A1 (es) * 2009-05-19 2011-06-22 Vivia Biotech Sl Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos
PL2432472T3 (pl) 2009-05-22 2020-03-31 Incyte Holdings Corporation 3-[4-(7H-Pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo]oktano- lub heptano-nitryle jako inhibitory JAK
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2509603A1 (en) 2009-12-09 2012-10-17 Biolinerx Ltd. Methods of improving cognitive functions
AR080357A1 (es) 2010-01-08 2012-04-04 Catabasis Pharmaceuticals Inc Derivados de fumaratos de acidos grasos, composiciones farmaceuticas y sus usos
MX354212B (es) 2010-03-10 2018-02-19 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2012154554A1 (en) * 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
KR102078044B1 (ko) 2011-09-19 2020-02-17 오렉쏘 에이비 오피오이드 의존증의 치료를 위한 남용-방지성 약학 조성물
US9642915B2 (en) * 2012-05-07 2017-05-09 Cellix Bio Private Limited Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
TWI634121B (zh) 2013-03-06 2018-09-01 英塞特控股公司 用於製備ｊａｋ抑制劑之方法及中間物
MX394928B (es) 2013-08-07 2025-03-24 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP3157936B1 (en) 2014-06-18 2018-10-17 Thetis Pharmaceuticals LLC Mineral amino-acid complexes of active agents
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CN104225615B (zh) * 2014-09-24 2017-02-01 东南大学 一种紫杉醇类磷脂化合物、其药物组合物及应用
WO2016198971A1 (en) * 2015-06-08 2016-12-15 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
US20190125702A1 (en) * 2016-03-15 2019-05-02 Vitality Biopharma, Inc. Methods and Compositions for the Treatment of Demyelinating Disorders
WO2017210604A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
PE20190403A1 (es) 2016-07-29 2019-03-13 Janssen Pharmaceutica Nv Metodos para tratar el cancer de prostata
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
HUE067471T2 (hu) 2018-03-30 2024-10-28 Incyte Corp Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
US10822346B2 (en) * 2018-04-17 2020-11-03 Cardurion Pharmaceuticals, Llc Meglumine salts of thienopyrimidines
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
US11643438B2 (en) 2018-07-20 2023-05-09 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use
EP3826684A4 (en) 2018-07-26 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
KR20210142152A (ko) * 2019-03-22 2021-11-24 인티그레이티드 나노테라퓨틱스 아이엔씨. 스캐폴드 모이어티로부터 제조된 지질 접합체
CA3160312A1 (en) 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
US20230064327A1 (en) 2020-01-22 2023-03-02 Seelos Therapeutics, Inc. Reducing side effects of nmda antagonists
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN119606959A (zh) * 2024-12-26 2025-03-14 典晶医药(无锡)有限公司 Tazofelone与紫杉类药物的组合物在治疗实体瘤中的应用

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US449A (en) * 1837-11-11 Improvement in the mode of preparing paint for the protection of buildings against fire
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621048A (en) 1968-03-14 1971-11-16 Colgate Palmolive Co Quaternary ammonium compounds
US4218234A (en) 1972-12-07 1980-08-19 Novex Rt. Soil conditioners
SU477159A1 (ru) 1973-07-27 1975-07-15 Всесоюзный научно-исследовательский институт фитопатологии Способ получени амидофосфорилоксиэтиламидов карбоновых кислот
AR208187A1 (es) 1973-12-05 1976-12-09 Pfizer Metodo para la preparacion derivados de n-carbamoil-2-feniletensulfonamida
JPS5186479A (en) 1975-01-22 1976-07-29 Asahi Chemical Ind 55 furuororashirujudotainoseizohoho
FR2298332A1 (fr) 1975-01-22 1976-08-20 Asahi Chemical Ind Nouveaux derives de 5-fluorouraciles
US4097597A (en) 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4351831A (en) 1977-11-02 1982-09-28 Massachusetts Institute Of Technology Process and composition for treating disorders by administering isoxsurpine and choline
US4185095A (en) 1977-11-23 1980-01-22 The Massachusetts General Hospital Nerve growth factor
US4287184A (en) 1977-11-23 1981-09-01 The Massachusetts General Hospital Process for healing wounds
US4407744A (en) 1977-11-23 1983-10-04 Young David M Process for obtaining nerve growth factor
CH622660GA3 (OSRAM) 1978-08-18 1981-04-30
JPS5553208A (en) 1978-10-13 1980-04-18 Mitsubishi Chem Ind Ltd Insecticide
IT7927748A0 (it) * 1979-11-30 1979-11-30 Simes Derivati dell'acido 6,6'-diapopsi psicarotenedioico e relativi procedimenti di preparazione.
US4408052A (en) 1980-02-27 1983-10-04 Takeda Chemical Industries, Ltd. Phospholipid carbamates
US4346085A (en) * 1980-02-29 1982-08-24 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
US4636494A (en) * 1981-01-30 1987-01-13 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
JPS58177953A (ja) * 1982-04-13 1983-10-18 Eisai Co Ltd ポリプレニルカルボン酸アミドおよびその製造方法
JPS5925327A (ja) 1982-07-31 1984-02-09 Hidematsu Hirai 抗腫瘍性複合体の製造方法
US4558049A (en) 1982-11-24 1985-12-10 Farmitalia Carlo Erba S.P.A. Antipsycotic benzoxazines
US5169762A (en) 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
JPS59204175A (ja) 1983-04-28 1984-11-19 Terumo Corp ５―フルオロウラシル誘導体を有効成分とする血小板凝集抑制剤
DE3476197D1 (en) 1983-08-01 1989-02-23 Mclean Hospital Corp Gaba esters and gaba analogue esters
WO1985001729A1 (fr) * 1983-10-20 1985-04-25 Terumo Kabushiki Kaisha Derives de 5-fluoro-uracyle et medicament les contenant
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
US4684646A (en) * 1984-06-26 1987-08-04 Merck & Co., Inc. 2-acylaminomethyl-1,4-benzodiazepine derivatives as CCK-antagonists
US4868161A (en) 1984-06-29 1989-09-19 City Of Hope Method for promoting nerve regeneration
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4554272A (en) * 1985-01-25 1985-11-19 Merck & Co., Inc. Substituted quinazolino-1,4-benzodiazepin-6,9-diones and their preparation
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
JPS61204136U (OSRAM) 1985-06-05 1986-12-23
US4729989A (en) 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4692441A (en) 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US5246726A (en) 1986-03-21 1993-09-21 Efamol Ltd. Iron-containing composition and method for treatment of cancer
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5459256A (en) 1987-04-17 1995-10-17 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Lipophilic, aminohydrolase-activated prodrugs
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
WO1989002733A1 (en) 1987-09-22 1989-04-06 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
ZA886890B (en) 1987-10-09 1989-05-30 Hoffmann La Roche Novel dideoxycytidine derivatives
US5420276A (en) 1987-11-03 1995-05-30 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
JPH01153629A (ja) 1987-12-11 1989-06-15 Nippon Oil & Fats Co Ltd 制癌剤
JPH01203331A (ja) 1988-02-05 1989-08-16 Rikagaku Kenkyusho 制癌剤
US4933324A (en) * 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
US4939174A (en) * 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US6107499A (en) 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
JPH01287022A (ja) 1988-05-12 1989-11-17 Nippon Oil & Fats Co Ltd 抗癌剤耐性克服剤
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
JP2612619B2 (ja) 1988-12-14 1997-05-21 財団法人相模中央化学研究所 含リン化合物よりなる経皮吸収促進剤
CH676909A5 (OSRAM) 1988-12-23 1991-03-28 Nestle Sa
HU207287B (en) 1989-01-17 1993-03-29 Biosignal Kutato Fejlesztoe Kf Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
GB8918294D0 (en) 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
JPH03236315A (ja) 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
GB9001121D0 (en) 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5545719A (en) 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5169764A (en) 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
JP3139777B2 (ja) 1990-08-27 2001-03-05 フマキラー株式会社 組換えダニアレルゲン
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
WO1992016554A1 (en) 1991-03-14 1992-10-01 The University Of Melbourne Protein allergens of the species cynodon dactylon
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
WO1992020362A1 (en) * 1991-05-14 1992-11-26 Shashoua Victor E Nerve growth peptides and uses therefor
DE4122722A1 (de) 1991-07-06 1993-01-07 Schering Ag Verfahren zur herstellung von indol-derivaten
US5227369A (en) 1991-07-11 1993-07-13 The Regents Of The University Of California Compositions and methods for inhibiting leukocyte adhesion to cns myelin
EP0616493A4 (en) 1991-12-10 1994-11-09 Rush Presbyterian St Luke METHODS AND COMPOSITIONS FOR REDUCING MULTIRESISTANCE TO MEDICINES.
US5369191A (en) * 1992-01-23 1994-11-29 Kureha Kagaku Kogyo K.K. Aromatic thioether ketone/thioether sulfone copolymer and production process thereof
IT1254517B (it) * 1992-03-06 1995-09-25 Indena Spa 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico
IT1254515B (it) * 1992-03-06 1995-09-25 Indena Spa Tassani di interesse oncologico, loro metodo di preparazione ed uso
US5214062A (en) 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
JPH0616548A (ja) 1992-06-30 1994-01-25 Sagami Chem Res Center 組織異常増殖抑制剤
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
DE4224737A1 (de) 1992-07-27 1994-02-03 Herbert Prof Dr Schott Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung
US5352596A (en) 1992-09-11 1994-10-04 The United States Of America As Represented By The Secretary Of Agriculture Pseudorabies virus deletion mutants involving the EPO and LLT genes
US5453521A (en) * 1992-10-05 1995-09-26 Rhone-Poulenc Rorer S.A. Process for obtaining 10-deacetylbaccatin III
FR2696461B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5356928A (en) * 1992-11-06 1994-10-18 Hauser Chemical Research, Inc. Cytotoxic agents
FR2697841B1 (fr) * 1992-11-12 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2698269B1 (fr) 1992-11-24 1995-01-06 Inst Nat Sante Rech Med Nouveaux médicaments à base d'acides gras insaturés, utilisables notamment comme antiagrégants plaquettaires et/ou comme transporteurs privilégiés vers le cerveau.
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
WO1994012530A1 (en) * 1992-11-30 1994-06-09 Biosignal Kutató Fejlesztó Kft. Polyunsaturated fatty acyl-peptide composition
FR2698871B1 (fr) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5496714A (en) 1992-12-09 1996-03-05 New England Biolabs, Inc. Modification of protein by use of a controllable interveining protein sequence
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
GB9301629D0 (en) 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
GB9304746D0 (en) 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5336684A (en) * 1993-04-26 1994-08-09 Hauser Chemical Research, Inc. Oxidation products of cephalomannine
FR2707293A1 (fr) * 1993-07-08 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
FR2712288B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712289B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5480799A (en) 1993-12-10 1996-01-02 The University Of North Carolina At Chapel Hill Sperm antigen corresponding to a sperm zona binding protein autoantigenic epitope
IT1264987B1 (it) 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604198A (en) 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
FR2721023B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
JPH0815133A (ja) 1994-06-29 1996-01-19 Hitachi Ltd 分析素子
FR2721928A1 (fr) * 1994-07-04 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US5597719A (en) 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
JPH0827010A (ja) 1994-07-19 1996-01-30 Nichinichi Seiyaku Kk 制癌免疫療法剤
WO1996004001A1 (en) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
NL9401743A (nl) 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
JPH08163991A (ja) 1994-12-15 1996-06-25 Mitsui Petrochem Ind Ltd タキサン型ジテルペンの製造方法
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
JPH11502509A (ja) 1995-01-16 1999-03-02 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション 治療用化合物 − 脂肪酸抱合体
EP0813416B1 (en) 1995-03-06 2005-05-25 Interneuron Pharmaceuticals Incorporated Reduction of infarct volume using citicoline
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
US5532374A (en) 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JPH0925231A (ja) 1995-07-13 1997-01-28 Sagami Chem Res Center 癌転移抑制剤
JPH0930963A (ja) 1995-07-21 1997-02-04 Nisshin Oil Mills Ltd:The 医療用油脂含有組成物
EP1021401A1 (en) 1995-09-21 2000-07-26 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
US5952317A (en) 1995-09-21 1999-09-14 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
AU770519B2 (en) 1996-05-22 2004-02-26 Luitpold Pharmaceuticals, Inc. DHA-pharmaceutical agent conjugates
CA2255615C (en) 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US5976784A (en) 1996-09-20 1999-11-02 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
CA2271135A1 (en) 1996-11-12 1998-05-22 Medivir Ab Nucleosides
JPH10168047A (ja) 1996-12-04 1998-06-23 Kao Corp アミド誘導体及びこれを含有する外用剤組成物
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
GB9804361D0 (en) 1998-03-02 1998-04-22 Scotia Holdings Plc Cancer treatment
US6136988A (en) 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
EP1163011A2 (en) 1999-03-09 2001-12-19 Protarga Inc. Fatty acid-anticancer conjugates and uses thereof
US6184164B1 (en) * 1999-04-28 2001-02-06 The University Of Houston Bimodal silicon nitride-bas ceramic composites
AU4834200A (en) 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
US6459645B2 (en) 1999-09-30 2002-10-01 Intel Corporation VPX bank architecture
US6710086B1 (en) 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
MXPA03009727A (es) 2001-04-26 2004-01-29 Control Delivery Sys Inc SISTEMA DE SUMINISTRO DE FaRMACOS DE LIBERACIoN PROLONGADA QUE CONTIENE COFARMACOS.

Also Published As

Publication number Publication date
EP0909183A2 (en) 1999-04-21
DE69730217D1 (de) 2004-09-16
ES2222514T3 (es) 2005-02-01
US7199151B2 (en) 2007-04-03
JP4402173B2 (ja) 2010-01-20
US5795909A (en) 1998-08-18
US6602902B2 (en) 2003-08-05
JP2000514405A (ja) 2000-10-31
EP0909183B1 (en) 2004-08-11
ATE273025T1 (de) 2004-08-15
AU3142597A (en) 1997-12-09
AU725759B2 (en) 2000-10-19
WO1997044063A3 (en) 1998-02-26
DK0909183T3 (da) 2004-12-20
CA2255614C (en) 2009-12-15
WO1997044063A2 (en) 1997-11-27
EP1466628A1 (en) 2004-10-13
US20040180949A1 (en) 2004-09-16
US20020010208A1 (en) 2002-01-24
CA2255614A1 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
DE69730217T2 (de) Dha-pharmazeutisches produkt konjugate
DE69329073T2 (de) In liposomen verkapseltes taxol und verwendungsverfahren
DE69811263T2 (de) Konjugierte linolsäure enthaltendes verteilungssystem in kosmetika
DE69526742T2 (de) Wundheilende zusammensetzungen zur behandlung von akne,die ein pyruvate,ein antioxidant und eine fettsäuremischung enthalten
DE69920497T2 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
DE60028384T2 (de) Propofol enthaltende anästhetische zusammensetzung zur intravenösen injektion
DE69731885T2 (de) Apoptose induzierende adamantyl-derivate und deren verwendung als antikrebsmittel
DE60217324T2 (de) Pharmazeutische zusammensetzung für die hormonersatztherapie
DE69425859T2 (de) Cyclosporin enthaltende Weichkapsel
DE60029602T2 (de) Lipasehemmer enthaltende dispersionsformulierungen
DE2818553A1 (de) Zusammensetzung zur behandlung von proliferativen hautkrankheiten
EP0241809A1 (de) Synergistische Kombination von Amantadin und Selegilin
EP0607231A1 (de) Verwendung einer emulsion, zur herstellung eines arzneimittels zur i.v.-verabreichung zur behandlung von hauterkrankungen.
EP1113795B1 (de) Tryptophanylester und deren n-acyl-derivate zur prävention und therapie von erkrankungen, die durch oxidationsprozesse verursacht oder verstärkt werden
DE60308888T2 (de) Injizierbare 2,6-diisopropylphenol enthaltende anästhetische zusammensetzung und verfahren
EP2671578A1 (en) Prophylactic or therapeutic drug for peripheral neuropathy caused by anticancer agent
DE60220666T2 (de) Steigerung der wirksamkeit von wirkstoffen durch micellare zubereitung mit retinolderivaten
DE2241742C3 (de) Verwendung von Hydroxyprolinderivaten bei der äußerlichen Behandlung von Bindegewebserkrankungen
DE2759171C2 (OSRAM)
DE4401554A1 (de) Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
DE69706241T2 (de) Pharmazeutische Zusammensetzung zur Behandlung der Leukämie enthaltend 9-cis-Retinoinsäure-alpha-Tocopherolester
DE60128801T2 (de) Isoflavone gegen strahlungsinduzierte Sterblichkeit
EP0176772B1 (de) Verfahren zur Retardierung von Vitamin C und E
DE602005003138T2 (de) Zusammensetzung in sprayform mit einer kombination aus clobetasolpropionat und calcitriol, einer alkoholphase und ölphase
DE60035613T2 (de) Topische,kosmetische und pharmazeutische Mittel,enthaltend spezifische alkoxylierte Diester der Fumarsäure

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: LUITPOLD PHARMACEUTICALS, INC., SHIRLEY, N.Y., US

8364 No opposition during term of opposition